However, studies have indicated modest benefits of DPP-4 inhibitors in T1DM, with reductions in HbA1c [16,17,18,19] and an improvement in time in glycemic target/range (TIR) [18]. The gene discussed is DPP4; the disease is type 1 diabetes mellitus.